2015
Lifetime Medical Costs of Knee Osteoarthritis Management in the United States: Impact of Extending Indications for Total Knee Arthroplasty
Losina E, Paltiel AD, Weinstein AM, Yelin E, Hunter DJ, Chen SP, Klara K, Suter LG, Solomon DH, Burbine SA, Walensky RP, Katz JN. Lifetime Medical Costs of Knee Osteoarthritis Management in the United States: Impact of Extending Indications for Total Knee Arthroplasty. Arthritis Care & Research 2015, 67: 203-215. PMID: 25048053, PMCID: PMC4422214, DOI: 10.1002/acr.22412.Peer-Reviewed Original ResearchConceptsTotal knee arthroplastyDirect medical costsOA patientsKnee osteoarthritisMedical costsKnee arthroplastyTKA utilizationEligibility criteriaEffective nonoperative therapiesKellgren/LawrenceKnee osteoarthritis managementKnee OA patientsSymptomatic knee osteoarthritisMulticenter Osteoarthritis StudyLifetime costsUtilization Project dataOsteoarthritis Policy ModelLifetime direct medical costsLifetime medical costsHealth care costsMedicare reimbursement schedulesTotal lifetime costsNonoperative therapySymptomatic osteoarthritisOsteoarthritis management
2005
An Asthma Policy Model
Paltiel A, Kuntz K, Weiss S, Fuhlbrigge A. An Asthma Policy Model. International Series In Operations Research & Management Science 2005, 70: 659-693. DOI: 10.1007/1-4020-8066-2_26.Peer-Reviewed Original Research
2002
Lifetime Cost of HIV Care in France during the Era of Highly Active Antiretroviral Therapy
Yazdanpanah Y, Goldie SJ, Losina E, Weinstein MC, Lebrun T, Paltiel AD, Seage GR, Leblanc G, Ajana F, Kimmel AD, Zhang H, Salamon R, Mouton Y, Freedberg KA. Lifetime Cost of HIV Care in France during the Era of Highly Active Antiretroviral Therapy. Antiviral Therapy 2002, 7: 257-266. PMID: 12553480, DOI: 10.1177/135965350200700405.Peer-Reviewed Original ResearchConceptsActive antiretroviral therapyHIV infectionCD4 strataAntiretroviral therapyHIV careHIV diseaseLifetime costsHighly Active Antiretroviral TherapyHigher CD4 strataHIV Clinical CohortLowest CD4 stratumCD4 cell countEra of HAARTBurden of diseaseStage of illnessCost of careHealth policy plannersHealth care costsClinical managementSpecific AIDSClinical cohortMean costFrench patientsCare costsCell count
2001
Cost-effectiveness of inhaled corticosteroids in adults with mild-to-moderate asthma: Results from the Asthma Policy Model
Paltiel AD, Fuhlbrigge AL, Kitch BT, Liljas B, Weiss ST, Neumann PJ, Kuntz KM. Cost-effectiveness of inhaled corticosteroids in adults with mild-to-moderate asthma: Results from the Asthma Policy Model. Journal Of Allergy And Clinical Immunology 2001, 108: 39-in4. PMID: 11447380, DOI: 10.1067/mai.2001.116289.Peer-Reviewed Original ResearchConceptsSymptom-free daysCorticosteroid therapyAcute exacerbationModerate asthmaHealth-related qualityPopulation of patientsCost-effectiveness findingsHealth care costsCost-effectiveness analysisTotal health costsAdult asthmaObservational cohortRandomized trialsPatient preferencesPatient surveyClinical impactCorticosteroidsSide effectsCare costsDrug efficacyNatural historyAsthmaIncremental costTherapyMild